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Abstract 
This Business Project was written as part of the Executive MBA at the International 
Hellenic University.  
We are living in a period when significant changes take place in the pharmaceutical 
industry. Many companies are facing significant patent challenges and health care sys-
tems are interacting partners of the pharmaceutical industry. 
This business plan is about the creation of an innovative Contract Research Organiza-
tion, a profitable business, whose main goal is to improve the interaction between the 
pharmaceutical industry and the care giving medical environment. This can only be 
achieved by creating values for shareholders, the pharmaceutical industry itself, physi-
cians, insurance companies and patients. At the same time the patient’s needs have to be 
in the focus of any development in the medical area. This company is aiming to have a 
patient-centric approach with a main mission to offer therapeutic solutions by improv-
ing patients’ lifestyle. It will offer as well consulting services and solution to pharma-
ceutical companies and will develop inhalation pharmaceutical solutions to treat specif-
ic diseases related to pulmonary disorders/lung diseases.  
The mission is to dedicate its expertise and resources to add exceptional values for the 
benefit of the patients who suffer from respiratory diseases, through providing and de-
veloping innovative services. In this way we will be helping people to live healthier and 
enjoy a better quality of life, while maximizing stakeholder’s value. The goal is to be-
come both a lifesaving innovative business and a cash-generating business. The strate-
gic plan of the company will be achieved in three phases. In Phase I the company focus-
es on all pharmaceutical companies that require consultancy and operational services for 
developing generic medicine to treat respiratory diseases, as well as clinical services. 
Phase II includes the building of an innovative company for developing respiratory 
medicine. Also contract clinical analysis will be offered. In Phase III generic drugs will 
be developed, manufactured and applied to patients. This project plan includes details 
about the specific activities of the company and the timeframe that is demanded for the 
company to complete all three phases. 
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Preface 
The pharmaceutical industry is an area which is becoming more and more attractive 
for a lot of investors worldwide. The number of patients suffering from various diseas-
es is increasing dramatically and this is why a lot of companies invest on new therapies 
and on the development of innovative molecules. This is mainly due to the aging popu-
lation which is accomopanied by significant increase in non-communicable diseases 
such as respiratory disorders [IHME, 2010]. For 2011, according to OECD data, life ex-
pectancy in Greece was at 80.8 years [OECD, 2010]. The following business plan in-
cludes the development of a pharmaceutical company with generic products which 
focuses on the respiratory and pulmonary diseases. Greece is a country which is facing 
nowadays a lot of challenges due to the recession and the financial crisis. This crisis 
directly affects the health care system and drive many EU countries and Greece spe-
cially to switch medication to generic lower cost ulternatives espicially with the signifi-
cant increase in Health care cost [OECD, 2015]. The particular business plan shows that 
there are still opportunities in Greece which can  bring profit for the shareholders of 
the company and can as well contribute to the flourishing of the country’s economy.  
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1. Introduction 
Pharmaceutical industry is an industry that has an important impact on the growth of 
the Greek economy, as today a number of pharmaceutical companies, Greek and mul-
tinational, operate in the Greek market and almost 132,000 people absorbed directly 
or indirectly by the pharmaceutical sector [IOBE, 2014].  The main challenge that the 
Greek economy faces in this area is the high expenditure on pharmaceuticals. Only in 
2009 Greece reported 2.4% of GDP/ €6.6 billion which made it the country with the 
highest expenditure in comparison to all the OECD (Organization for Economic Co-
operation and Development) countries. For this reason the government proceeded to 
a cut down on the pharmaceutical prices by 20% so as to minimize the expenditure but 
this proved to be ineffective because the following year the pharmaceutical expendi-
ture of Greece was 2.6% of GDP. Due to its crucial financial condition, Greece decided 
to sign an agreement with the international counterparts based on which, a package of 
€110 billion would be provided to Greece with the obligation to implement strict 
measures and fundamental reforms in every sector of the economy [Hellenic Statistical 
Authority, 2012]. This Economic Adjustment Programme included reduction of the 
pharmaceutical expenditure by 1.33% until 2012 and by 1.6% until 2014 so as to keep 
the public spending below 6.6% of the GDP. All these measures had a significant im-
pact on the operation of the healthcare systems and of course on the pricing and 
availability of the pharmaceutical products [IOBE, 2014]. 
2. Challenges that the pharmaceutical industry is facing 
2.1 Sustainability of the health system 
For the first time in 50 years sustainability of the health system is one of the major 
challenges facing the Greek state and society. Pharmaceuticals are a fraction only 20% 
of the overall healthcare budget with the other 80% accounted for by other suppliers 
and cost centers [Hellenic state budget, 2014]. Pharmaceutical treatments contribute 
to shorter hospitalization times and faster recovery, thereby reducing costs in other 
areas of healthcare. The past six years, pharmaceutical expenditure has been reduced 
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by 55% through sudden measures [IOBE, 2014]. However, extensive cut of pharmaceu-
tical expenditure results in counterproductive and it results in deterioration of public 
health, so that the cost of necessary additional healthcare outweighs the targeted sav-
ings on pharmaceutical costs. It is necessary for the government to follow a policy 
based on innovation and on the enhancement of the growth potential. In addition to 
this, adequate funding of the Greek health care organization EOPYY is needed and fair 
allocation of costs across all of its providers [ΕSYΝΕΤ, 2013]. Investment in innovation 
should be a high priority so as to protect and improve human health and save re-
sources in the health system by reducing hospitalization costs and avoiding invasive 
practices. 
2.2 Profit margins 
Since 2010, after the bailout program that Greece has agreed on with the Troika, the 
Greek Government decided to cut down on the pharmaceutical spending and keep it 
within the €2 billion limit [SFEE, 2013]. For that reason it introduced many strict 
measures. The reforms that followed led to the specification of the profit margins, the 
rebates and the discounts of wholesalers and pharmacists so as the goals of the phar-
maceutical policy to be achieved. To this direction rebates were increased from 9% to 
11% for on-patent drugs and quarterly claw back has been decided to be imposed if 
the bimonthly targets for expenditure have been surpassed [SFEE, 2013]. As a result, 
the profit margins have diminished for those global pharmaceutical companies operat-
ing in Greece owing to huge price cuts and discounts, delays in access of innovative 
drugs and obligations for paybacks to keep the budget within the set limits. 
2.3 Pricing of medicinal products 
As far as it concerns the drug prices, it has been decided that the maximum price of 
the reference on-patent medicinal products as regards the first patent of the active 
substance is defined as the average of three lower prices of the member states of the 
European Union [Yfantopoulos J., 2007]. The maximum price of generics is defined at 
65% of the price of the respective reference medicinal product whose patent protec-
tion has expired. When more than one generic obtain a marketing authorisation, a dy-
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namic pricing applies based on the sales volume. Twice in a year, full prices revision is 
affected and in the meantime pricing of new medicinal products is performed [SFEE, 
2013]. 
2.4 Patient access 
All the changes that have been performed in the Greek health care system have an im-
pact on the patient access. It is important to focus on the adoption of a patient-
oriented policy involving respect for humans and commitment to the actual needs of 
the Greek society [WHO1, 2015]. Also, prevention and early diagnosis should be em-
phasized as well as provision of essential information to patients, streamlined primary 
care and high-quality hospital care. In addition to this, patients should have unhin-
dered access to innovative medicine and technologies that can change health out-
comes, reduce mortality and avoid hospitalization. Greek citizens should have proper 
access to high-quality and high-efficacy treatments on an equal footing with other Eu-
ropeans which will improve the health of the population. 
3. Methods 
3.1 Interviews with stakeholders 
In order to get an in-depth analysis of the current situation in the pharmaceutical sec-
tor in Greece, systematic designed interviews have been conducted with managers of 
both multinational and Greek pharmaceutical companies who control the departments 
of the inhalation products in Greece. In addition to this, managers from companies 
which don’t distribute their medicine to Greece present their perception of the Greek 
market and the reasons for not entering in it. The questions that have been asked in-
clude the critical success factors of operating in Greece, the current risks that exist, the 
opportunities that are offered, the main focus of the respiratory market in Greece, the 
growth of the market and the strategy that the companies follow so as to continue to 
operate in Greece. As far as it concerns the companies that are not operating in 
Greece, the reasons for this decision have been asked as well as the differences be-
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tween the Greek and the European pharmaceutical market. The key findings of the in-
terviews are summarized in the appendix. 
 
Based on the outcomes of the interviews, we realize that the main problem that the 
pharmaceutical sector in Greece faces is the instability of the medicine prices, which is 
linked to unpredictable continuous reform in the healthcare sector by the Greek gov-
ernment. The respiratory market is focusing mainly on asthma and Chronic Obstructive 
Pulmonary Diseases (COPD). The fact that new innovative medicines are introduced 
contributes to the overall increase in sales. On the other side, the Greek market is ge-
nericized, which offer opportunities for local companies to develop and launch more 
cost effective generic therapies that provide the adequate patient care while achieve 
the government saving target in health care. This will also enable a higher patient ac-
cess to efficient therapies.    
The identified critical success factors for any start-up Greek pharmaceutical company 
are: 
1. The creation of high quality products at more affordable prices for patients and 
payors. 
2. Focus on productivity and operational efficiency. 
3. Being able to recognize the given opportunity. 
4. Drive innovation in every aspect of the business. 
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4. Selection of the disease area 
The main focus of this particular business project is on the respiratory disease area be-
cause of the fact that pulmonary disorders are often chronic with good prospects for 
long term therapy. In addition to this, the patient population is increasing continuously 
and many respiratory diseases have a high public profile. Furthermore, there is a high 
demand for cheaper respiratory products in Greece, which means that the develop-
ment of generic respiratory medicine has become a priority for many pharmaceutical 
companies. This is mainly as generic inhaled products are difficult to copy due to the 
combination of complicated medical devices with difficult to formulate molecules and 
hence the generic price erosion is slow and the profit margin is high [Visiongain, 2009]. 
4.1 Introduction 
Lung diseases are a major concern to the world because of the fact that they are the 
reason why one sixth of all deaths are caused. One in eight of all deaths are due to 
respiratory disease, nowadays, in the EU and the hospital cases of lung conditions are 
at least 6 million [IHME, 2010]. In our decade, the impact of this disease is very strong 
and it will continue to raise a lot of worries in the future as well. 
 
  -6- 
Figure 1: Age-standardised mortality rate for all respiratory diseases within the EU [Source WHO, 
2011] 
People who suffer from lung diseases face the possibility of premature death or of 
other various disabilities. This disorder has a significant cost because the primary and 
hospital care as well as the other therapies that follow are quite expensive [European 
Lung Foundation, 2015]. Also, one more negative effect of lung diseases is the fact that 
patients are not as productive as before because sometimes they are not capable of 
working. Below some figures, which have to do with calculations of the economic bur-
den, are presented. 
Table 1: Aggregated annual direct and indirect costs and the value of disability-Adjusted Life-Years 
(DALYs) lost for EU countries in billions of Eur at 2011 rate [European Lung Foundation, 2011] 
 
4.2 The most common respiratory diseases 
The two most common respiratory diseases, that all the pharmaceutical companies in 
Greece focus on, are Asthma and Chronic Obstructive Pulmonary Disease (COPD). 
4.2.1 Asthma 
Asthma is a long term condition which causes inflammation in the patient’s airways. It 
is considered to be a common disease and we can find three types of asthma. The first 
type is the adult asthma which has appeared in childhood and it has continued into 
adulthood [EAACI, 2015]. The second type is the asthma that occurred only in adult-
hood and the third type is the one that developed in childhood and then suddenly dis-
appeared. Adult asthma is often related to allergies and followed by other allergic 
conditions, for instance, hay fever. It is more likely to find women patients suffering 
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from adult asthma and an amount of around 10% of patients develop severe asthma 
[European Lung Foundation, 2011]. In Greece 8.6% suffer from asthma and in the 
whole Europe 10 million people confront this difficult disease [EAACI, 2015]. According 
to researches, 33% of the population is going to develop asthma at some point in their 
life between the age of 5 and 80 years old with most probabilities before the age of 20 
[IMS, 2014]. A map follows which shows the geographical distribution of the disease. 
These differences are probably due to climatic conditions of different regions and dif-
ferent exposure to irritants and allergens of the environment. 
 
Figure 2: Geographical distribution of asthma in Greece [Source: Myasthma, 2015] 
4.2.2 Chronic Obstructive Pulmonary Disease (COPD) 
Chronic obstructive pulmonary disease (COPD) is characterized by persistent airflow 
limitation that is usually progressive and associated with an enhanced chronic inflam-
matory response in the airways and the lung to noxious gases or particles [GOLD, 
2014]. COPD is the third cause of death worldwide and in 2010 4.8% of the population 
was detected with COPD globally [WHO, 2011]. Although it is a disorder that is proved 
to be severe in many cases, it can be prevented and commonly treated, according to 
the report of the Global Initiative Obstructive Lung Disease (GOLD) in 2014. Unfortu-
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nately, an important amount of patients until today has not been diagnosed or it re-
mains misdiagnosed. The fact that spirometry is not correctly and widely used as a di-
agnostic method and that physicians are not fully aware of the clinical features of 
COPD or even sometimes fail to distinguish between asthma and COPD, raises the 
number of undiagnosed or misdiagnosed patients. In addition to this, patients fail to 
pay the attention that is needed to the symptoms of COPD that appear as chronic 
cough, difficulties in breathing, sputum production Because of the fact that COPD is a 
costly disease for the healthcare system and like asthma it causes loss of productivity 
as well, it is a burden to the society. Its prevalence in Greece was estimated between 
3% and 18.4% and in Europe these rates are estimated between 2.1% and 26.1% ac-
cording to the age of the patients, the country and the tools that are used [Tzanakis N. 
et. al., 2004]. Treatment options include lung reduction surgery, smoking cessation and 
lung transplant. Symptomatic therapy is aimed at reducing bronchoconstriction and 
inflammation. Bronchodilators, anticholinergics, theophylline, corticosteroids and an-
tibiotics may be prescribed. Apart from this, oxygen therapy and pulmonary rehabilita-
tion are helpful in many patients, with an influenza vaccine being given annually and 
the pneumococcal vaccine being given once and again after 10 years [IMS, 2014]. 
Table 2: Characteristics of newly diagnosed patients with COPD in Greece [Source: Dovepress, 2014] 
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5. Market Analysis 
5.1 Geographical breakdown of the respiratory market 
The largest market share in the respiratory market is held by North America and then 
Europe follows. In the Asia-Pacific and Latin America, the market is still small from the 
sales perspective but rapidly grow volume-wise. It has been also observed that after 
the expiry of many brands, a big number of respiratory generic alternatives has been 
developed by local companies at lower cost.  The number of patients suffering from 
Asthma and COPD in these developing markets is increasing steadily, the market share 
that Asia-Pacific has nowadays will increase significantly in 2020 [IMS, 2014]. The 
graph below represent the size and forecast of the respiratory market for the two main 
respiratory diseases, COPD and Asthma. In addition, the following table summarize top 
respiratory brands in the US which represents the largest market share. 
 
Figure 3: Global COPD and Asthma market per inhaler type 2013-2020 [Source: Allied Market Re-
search, 2013] 
Table 3: Top 25 respiratory brands in the US [Source: IMS, 2015] 
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5.2 The pharmaceutical companies working in the respiratory area 
GlaxoSmithKline (GSK) is the first player in the respiratory market due to Advair®, a 
combination drug that is the leading product in the respiratory disorder market, and to 
Breo Ellipta and Anoro Ellipta the new latest therapies that it has developed [Data-
Monitor, 2015]. It is forecasted that the two new respiratory products of GSK will be 
generating in 2018 sales of around $2 billion. Boehringer Ingelheim with the Spiriva 
and Combivent franchises increased its sales at the volume of 6.5 billion in 2014. This 
made it the second largest company in the respiratory area worldwide [IMS, 2015]. 
Other companies which play a key role in the respiratory market are AstraZeneca, via 
Symbicort® franchise, Novartis and Merck & Co. Below there is a table with the leading 
respiratory drugs in 2018. Boehringer Ingelheim is excluded from consensus forecast 
sales because of its private ownership status [Bloomberg1, 2015]. 
Table 4: Leading respiratory brands in 2018 [Source: Bloomberg
1
, 2015] 
 
5.3 Respiratory market in Greece 
The Greek pharmaceutical market is considered by many companies a low cost market 
that is why they do not enter the Greek market. However, today in the Greek respira-
tory market an important number of companies manufacture and distribute their med-
icine in Greece and own a percentage of the market share. The company with the 
higher sales is GlaxoSmithKline with its products Seretide®, Aerolin®, Becotide®, 
Serevent® and Flixotide® [Pulmonologist, 2015]. AstraZeneca is as well a key player in 
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the Greek market with Symbicort®, Pulmicort®, Oxez® and Dracanyl®. Also, Boehringer 
Ingelheim has a strong presence in the Greek market with Spiriva®, Spiriva® 
Respimat®, Atrovent® and Berovent®. Novartis has presented lately two new products, 
Onbrez® and Seebri® and these two in addition to Foradil® make Novartis an important 
player as well [Pneumologist, 2015]. In addition, we find in the Greek market Foster 
and Clenil Fortojet which belong to Chiesi an Italian family owned company and ELPEN 
which is a promising Greek company with branded generics and original products like 
Formopen®, Fluticapen®, Rolenium®, and Pulmoton®. Ranking out of 400 companies 
ELPEN has the sixth place and its revenues are steadily growing year by year, despite 
the price reduction of the medicine and the claw backs and rebates that the Greek 
government is enforcing [Elpen, 2015]. Allertec, Nycomed, Rafarm, Merck and UCB are 
the other companies which operate in the Greek market. 
5.4 The generic market 
Generic is a drug that shares the same qualitative characteristics with the reference 
product. It has the same strength as far as it concerns the active substance and it can 
be characterized as bioequivalent to the original one [FDA, 2015].  Generics can be 
classified in branded generics, which have a specific brand name, and unbranded, 
which use the international non-proprietary name and the name of the company. The 
increase of efficiency in pharmaceutical spending is something to which the develop-
ment of generics will contribute, according to all OECD countries. However, many 
countries do not fully exploit the potential that generics offer to them and as a result, 
they represent a very small percentage of their market share [OECD2, 2015]. Further, 
we will see the attitude of Greece towards them and the reasons for this. 
5.4.1 Worldwide use of generics 
Generics accounted for more than three quarters of the volume of pharmaceutical sold 
in the United States, United Kingdom, Chile, Germany and New Zealand for 2013, 
whereas in Luxembourg, Switzerland, Italy and Greece, they represented less that one 
quarter of the volume [EGA, 2011]. Generics have always been considered as an essen-
tial part of the healthcare delivery system across Europe. They have stimulated the 
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competition within the pharmaceutical sector to the benefit of the beneficiaries and 
they also offer direct savings to the economy of the country [Frenk J. & Moon S., 
2013]. Despite this, generic market penetrance is not something that we find in the EU 
countries because of various reasons. To begin with, there is lack of coherent policies 
and variations in reimbursement in the country members of the EU. Additionally, there 
are major differences in the overall management of the countries’ National Healthcare 
Systems. In the majority of OECD countries, pharmacists can substitute brand-name 
medicine with generics. Generic substitution is mandatory in some countries like Den-
mark, Finland, Spain and Italy. New Zealand and United Kingdom have high generic 
penetration without any substitution mandate. The Netherlands, Germany and New 
Zealand have used tendering, in order to exert pressure on generic prices while other 
countries prefer regulating the price of the originator. In Canada, several provinces 
have introduced or reduced the reimbursement prices of generics included in public 
plans’ formularies since 2010. This had as a result, generic price caps to be around 25% 
of the brand name product’s price [WHO2, 2015]. 
5.4.2 Generics in Greece 
Medicines are one of the Greece’s biggest imports. According to the IMS, foreign-made 
drugs make up about 88% of Greece’s pharmaceutical market [IMS, 2015]. Greece al-
ways had the highest pharmaceutical healthcare expenditure and the lowest generic 
market share [Bloomberg2, 2015]. Recently, due to the deep recession, Greek NHS 
adopted cost-saving measures like the promotion of generic consumption against orig-
inal drugs with patient copayments, and media-based strategy to reverse prescribing 
habits. Greece has been slow to adapt generics in the therapies of patients because of 
the fact that the country has had low prices for branded drugs relative to the other Eu-
ropean countries, and relatively high prices for generics. The target that was set by the 
Health Minister in 2014 was to increase the share of generics to at least 30% by the 
end of 2014 and triple it to 60% by the end of 2015, thing that has not yet been ac-
complished [Bloomberg2, 2015]. In addition to this, because of the fact that Greek 
pharmaceutical companies had not produced many generic products, the country had 
to import them from other countries. Some of those countries belonged to the third 
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world countries that is why a lot of questions were raised as far as it concerned the 
origin and the conditions under which they have been produced. These formulations 
are globally controversial and are a subject of many negative articles and reports in 
major news bullets around the world. In some cases, medicines have withdrawn sum-
marily because of the serious side effects that they caused. This caused more skepti-
cism to the patients, thing that can be dealt with, with the creation of Greek generics 
that will strengthen the presence of the Greek pharmaceutical companies in the mar-
ket [EGA, 2011]. This will ensure as well the quality and reliability of the products and 
jobs can be secured. Overall, by following this policy, the Greek pharmaceutical indus-
try can be significantly supported. 
5.4.3 Patients’ perception of generic products 
The perception of the generics in Greece is characterized by polarized opinions as 
many patients, even nowadays, do not fully trust the use of generics. They share the 
belief that the promotion of generics serves political interests and the interests of mul-
tinational pharmaceutical companies. Furthermore, they doubt about the effective-
ness of those products as they feel that they are not as effective as the brand-name 
products [Skaltsas LN. and Vasileiou KZ., 2015]. In addition to this, for some people ge-
nerics pose a safety risk that is why they are not in favor of their use. However, their 
lower price is a significant incentive for others, as due to the financial crisis they can no 
longer afford to buy brand-name products [OECD2, 2015]. The main reason that has 
caused this negative climate around generics is misinformation; that is why the im-
provement of the patient’s confidence towards generics is of high importance. This can 
be done with the provision of information in the areas of equivalency and regulation 
about the specific products. Trusted healthcare professionals should provide clear ed-
ucation about the equivalency of generic formulation and effective information should 
be communicated to patients not only through doctors but through pharmacists as 
well. Their usage and acceptance should be promoted so as to help the government 
reduce a great amount of its pharmaceutical expenditure and give space to Greek 
pharmaceutical companies to enter the market with the development of brand-name 
or unbranded generics [Natz A., 2012; Volger S., 2012]. 
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6. Business plan 
Although the times we are experiencing are full of challenges, opportunities rise for 
businesses which take advantage of the new trends in the Greek market. As it was 
pointed by the managers of several pharmaceutical companies, generics will take over 
the Greek market, as it is fully supported by the governmental policy. The design of the 
Panakia business plan will be described in this section as well as its objectives, vision, 
mission and goals. 
6.1 Business objectives 
As this company will develop generic respiratory medicine to treat diseases related to pulmo-
nary disorders, the goal of the company is to provide the patients with medicine that are af-
fordable, effective and safe to use. Since it is very common nowadays to find reluctant patients 
towards generics, the company should have as its priority the quality assurance of its products. 
In addition to this, Panakia will be a company that offers consulting services and solutions to 
other pharmaceutical services so as to ensure that the patients benefit from the highest quali-
ty and the innovative methods of production of its products. In addition, one of the main ob-
jectives of the company is to create value for all stakeholders and support the Greek society by 
employing more than 100 qualified associates and scientist within the first five years. We aim 
to achieve the breakeven point after 5 years and achieve a EBIDTA of > 25 million USD. Panakia 
will continue to be a privately owned company to ensure consistent long-term investment fo-
cus in R&D and hence in company growth and staying socially responsible for economic growth 
in Greece.  
6.1.1 Vision 
The vision of Panakia is to become one of the most valued pharma companies in 
Greece by developing and manufacturing respiratory medicine that comply with the 
highest regulatory standards. We want to secure the customer preference and to be 
the success partner of choice providing services and products with maximum added 
value to the whole health community. 
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6.1.2 Mission 
The company is aiming to offer distinctive products and services that satisfy the cus-
tomers’ needs. In order to do so, the most advanced technologies will be employed 
and together with the expertise, resources and passion, it will enable patients with 
respiratory problems to lead a healthy and quality life. Furthermore, Panakia is going 
to invest on people and on the environment to add exceptional values in the Greek 
market and to expand as well its presence abroad. 
6.1.3 Goals 
The goal of the company is to become a dynamic and powerful leader between the 
Greek pharmaceutical companies. Additionally, Panakia’s target is to develop strategic 
alliances with pharma companies and become a lifesaving company and a cash-
generating business that creates value for its stakeholders. 
6.2 Business strategy 
Because of the fact that respiratory disorders are on the rise and the nature of these 
diseases is often chronic, pharmaceutical companies will see a steady growth for most 
drug categories. The market of respiratory medicine will be worth in 68,176 billion USD 
in 2024 and future opportunities for respiratory therapeutics can be focused in the 
emerging markets [IMS, 2015]. Combination drugs will continue to dominate the mar-
ket and biotechnological molecules, especially monoclonal antibodies, will experience 
high growth in this market. Furthermore, the first generation drug molecules are going 
out of patent and many generic companies are looking for opportunities to enter the 
market but without having any experience. Also, the big pharmaceutical companies 
focus on developing new inhalation products and they prefer not to proceed with the 
manufacturing process. This offers significant opportunities to our company to become 
one of the partners of such companies. 
Giant pharmaceutical companies are the only players in this market that are financially 
capable of launching and marketing such complicated products as inhalation medicine. 
However large companies face major challenges with regards to the decision making 
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procedures, work efficiency and innovation. They have focused their major resources 
in late stage development of medical drugs, while relying on small contract research 
organizations to bring innovation and speed on board. The fact that the development 
of a drug is so complex resulted in the cooperation between big pharmaceutical com-
panies and smaller ones. Panakia has developed a 3-phased plan so as to accomplish 
all of its goals that were mentioned before. 
6.2.1 Phase 1 
At this early phase and for the next four years, Panakia will offer consultancy and busi-
ness intelligence services in the respiratory area with a focus on patient care. Through 
this, it can assist pharmaceutical companies in the respiratory area so as to guide their 
development program to the most attractive business areas. Also, it will offer analyti-
cal and clinical services for pharmaceutical companies and other organization to sup-
port the development of inhalation products. The operational laboratories will start by 
offering technical analytical services within 3 months and full analytical services within 
the first eighteen months. 
6.2.2 Phase 2 
In Phase II, which will last from 4 to 10 years, the company will built a manufacturing 
facility to offer services for pharmaceutical companies and other organizations to sup-
port mainly the development of inhalation products as well as oral dosage forms and 
this manufacturing facility will be used to support the clinical trials. Also, the company 
will enter into technology collaborations with pharmaceutical company partners to ex-
ploit the generic and branded markets for the development of high-value pulmonary 
products. By doing this, customers who are interested in developing Respiratory care 
medicines will be attracted. Through this, good prospects of progressing into com-
pound development through collaborations are offered, and additionally, great oppor-
tunities to grow long-term revenues. 
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6.2.3 Phase 3 
In the last phase, Phase III, we are planning to collaborate with strategic partners to 
market product lines across global markets and develop pulmonary products or brand-
ed generics to effectively manage all respiratory diseases and disorders. The last busi-
ness phase will start from year ten onwards and it will allow an efficient and innovative 
development of new therapies.  This phase offers the potential to gain market leader-
ship with limited resources and to improve our competency in the disease area. In ad-
dition to this we will have the flexibility to expand based on the demand that may rise 
based on market trends. 
6.3 SWOT Analysis 
  It is very important to identify the company’s strengths and weaknesses so as to focus 
on the disadvantages and the obstacles that Panakia may have to confront with and to 
take advantage of the opportunities that we are given. To start with, as it was men-
tioned before, the future of the pharmaceutical market in Greece is the development 
of generic medicine and the creation of companies who may offer analytical and con-
sultancy services to big pharmaceutical firms. In addition to this, the geographical posi-
tion of Greece is considered to be ideal for the distribution of medicine and let us not 
forget that the government is following a policy that promotes Greek medicine and 
gives important tax relief to companies that invest on R&D. The development of tech-
nology and the new methods that are being used nowadays for the production of med-
icine is a tool that enables the company to achieve the creation of high quality prod-
ucts and provide a cost efficient contract manufacturing services for large pharma. Fur-
thermore, the increasing number of patients who suffer from pulmonary diseases is an 
incentive in order for our company to invest and develop new therapies for the respir-
atory market. However, Panakia is a start-up company and it has not established a 
network yet or present evidence of previous success. In order for the company to 
achieve its goals an important amount of time is needed and apart from this the com-
pany has to deal with the instability of the economic and political environment in 
Greece and the reduction of prices that it enforces together with the rebates and 
clawbacks. Also, Panakia faces the impact of the financial crisis that occurs in Greece 
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since 2010 and it will have to confront with the other pharmaceutical companies that 
have started appearing or already exist in the Greek market and globally. 
 
Figure 4: SWOT analysis for PANAKIA Pharma. 
6.4 Scheduling 
As it was mentioned before, this particular business plan will be implemented in three 
phases and in each phase specific tasks should be carried out. In the first phase, the 
location of the company will be selected together with the equipment of the opera-
tional laboratories. After the creation of the laboratories, the selection of the employ-
ees of the company will take place and the development of the analytical services as 
well. We will continue with the development of the department of business intelli-
gence services and after all this an evaluation of the whole phase will be done. In the 
second phase, which is the most complex, the development of the medicine is going to 
be achieved by following specific steps. In the beginning, the manufacturing facility for 
the development of inhalation products will be built. The next steps are the prelimi-
nary Lab Batch, pre formulation on Batch, first generation formulation development, 
final formulation, pharmacokinetics, toxicology support and registration of the prod-
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ucts. Phase 3 includes training programs about respiratory disorders, collaboration 
movements for further expansion and the creation of communication channels be-
tween patients, health care specialists and the pharma industry. The project is starting 
on 1/1/2016 and will have to be completed before January 2034. The duration is quite 
long but let’s not forget that we are referring to the development of pharmaceutical 
products and services that require a lot of time.  
Table 5: Panakia Pharma Gantt chart schedule 
 
6.5 Project Organizational Plan 
This project is very demanding and complex that is why it is very important to identify 
and clarify from the beginning the departments of the company and the role that they 
will have so as to function properly. Below, an organizational plan is presented analyti-
cally at Figure 5 showing the exact number of departments that Panakia is going to be 
consisted of. 
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Figure 5: Organization chart for PANAKIA Pharma. 
6.6 Growth strategy of the company 
The strategy will be focused apart from the consulting and analytical part that it was 
described before, mainly on developing cost effective respiratory generic therapies, 
especially for emerging new markets as well as developed markets since the U.S.A and 
the European markets will experience several patent expiring. Except for this, the mar-
keting sector plays an important role to the future and success of the company. That is 
why we are going to start the advertisement from the company’s website with de-
tailed description of the company’s services and products. In addition to this, the 
members of the company are going to attend conferences globally where the services 
can be communicated to the customers. Apart from this, the company is willing to of-
fer free services for potential customers as a way to show the capabilities of the com-
pany and discounts to top customers. One more thing that is going to be very appeal-
ing to our customers will be the annual customer survey, which we will seriously con-
duct and publish to evaluate customer assessment and to define ways of continuous 
improvement. We should not underestimate our customers, so getting feedback from 
them will be in our priorities. Finally, we will try to raise public support and awareness 
through extensive public relationship and media activities. The provision of infor-
mation in the area of generics is extremely important. As it was mentioned before, 
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many patients fail to trust generics and as a result they turn to the original medicine. 
Because of the fact that the development of generics will be the key factor to the in-
crease of the company’s revenue, the negative perception of the patients should be 
changed. For this reason we will try to have a direct access to the doctors who will be 
specialized in this area, so as to have a clear view about our products and their effec-
tiveness. With their turn, they can inform properly and responsibly the patients and 
promote the use of generics. Our goal is to maintain a 30 day inventory credit policy 
with suppliers and also our gross revenue to cover 70-80% of all fixed costs (salaries, 
rent, IT hardware) in any given year except for the first two year. 
6.7 Constraints 
 For all the new products that Panakia will develop, the company will hold the patent 
even if it will have developed some particular products on behalf of a bigger pharma-
ceutical company, with which it will cooperate. As far as it concerns the area of human 
rights, labor, environment and anti-corruption, Panakia will follow the principals of the 
United Nations Global Compact. All instruments of the company will comply with 
21CFR part 11 guideline and the manufacturing facility will comply with current Good 
Manufacturing Practice, DIN EN ISO 9001:2000 and DIN EN ISO 13485:2001. This will 
make Panakia attractive as contract manufacturing and partner for pharma companies 
worldwide. The company will follow as well a diversity and inclusion strategy in which 
it will offer equal opportunities for all employees but also focus on creating attractive 
jobs for young graduates. Transparency will be established as main policy not only to-
ward internal associates but also toward our customers, governmental organization, 
physicians and patients. 
7. Financial analysis 
The financial plan of Panakia is executed in three phases so the financial analysis will 
take into consideration this implementation. Each phase will be implemented sepa-
rately that is why a different analysis in each stage will take place. Firstly the share-
holding of Panakia will be analyzed. 
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Table 6: Panakia Pharma financial analysis 
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7.1 Shareholding of Panakia 
The three founders of the company, Banika V., Eskandar F. and a third partner to be 
defined are going to supply to the company €80,000 each one of them. The sharehold-
ing of Panakia is as follows: 
Table 7: Shareholders of Panakia 
       NAME             % SHARES  OWNED CAPITAL [Eur] 
Banika V. 33.3% 80,000 
Eskandar F. 33,3% 80,000 
TBD 33,3% 80,000 
Total 100% 240,000 
7.1.2 Financial Plan of Phase 1 
In order for this business plan to come into reality, a significant amount of money will 
be needed. To begin with, the plan needs to be executed in a rental laboratory at the 
suburbs of Thessaloniki in an area near the Macedonia airport. The cost of the rent is 
calculated to be approximately 100’000 euros per year. Furthermore, apart from the 
availability of own capital by the founders of the company, the remaining required 
amount will be funded through a bank credit and through an external investor. For 
Phase I of the project, €8.7 million is needed, of which 30% will go to the creation of 
the laboratories and 70% to the development of analytical services and to the consul-
tancy and operational services. Some costs that are included in this amount are the 
laboratory equipment, the salaries of the people working in the company, including 
the salaries of the founders, IT hardware and the money that is required so as to ad-
vertise the company. The breakeven point of this phase is within the first five years. 
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Table 8: Financial summary of phase 1  
Start-up capital (million euros) 8.0 
Total investment 55.2 
Net present value 35.5 
Interest rate of return 31.3% 
Breakeven point 5 years 
7.1.3 Financial plan of Phase 2 
For the second phase of the plant, the breakeven point is calculated to be within two 
years. The investment in phase one is included as well here in the financial evaluations 
and we end up with the following table: 
Table 9: Financial summary of Phase 2 
Start-up capital (million euros) 11.4 
Total investment 57.7 
Net present value 40.6 
Interest rate of return  43.0% 
Breakeven point 2 years 
7.1.4 Financial plan of phase 3 
As we can see further, in this phase because of the fact that we have a high estimated 
owned and foreign capital interest due to the high risk that characterizes this particular 
phase, The IRR and NPV are lower than the previous phases. This does not mean that 
this phase should be extracted by the plant but in the long term it will develop further 
and bring the desirable results together with the other phases. 
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Table 10: Financial summary of Phase 3 
Start-up capital (million euros) 35.5 
Total investment 162.9 
Net present value 17.4 
Interest rate of return  10.0% 
Breakeven point 5 years 
The target of Panakia is to succeed to have a 30day inventory credit policy with its sup-
pliers. In addition to this, in any given year except for the first one, the gross revenue of 
Panakia should cover 70-80% of all fixed costs including salaries, rent, IT. 
7.2 Funding plan 
As it was mentioned before, the funders of the company will supply to the company 
the amount of €240,000, with an equal share for each one of them. Through a bank 
lawn the 2 million euros will be covered and additionally a turn to the venture capital 
market is essential for such a big investment. Because of the fact that it is quite diffi-
cult to attract the attention of venture capital firms, we will get a referral from a finan-
cial professional, either our lawyer or our banker, and then try to get through to them. 
By turning to venture capital firms we will be able to enhance the credibility and repu-
tation of this new venture and our network will be extended. In addition to this, we 
will be introduced to excellent and very capable employees, thing very important for 
the success of our company. Because of the fact that the market of generics is becom-
ing very attractive lately, especially in Greece where the government is pushing all the 
health stakeholders to this direction, there is a high possibility that several venture 
capital firms are going to be interested in this project. 
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8. High level risk analysis 
The pharmaceutical industry is an industry in which risk management plays a very im-
portant role to its development. The high risk level that describes it is due to the com-
plexity, the big length and size that it characterizes it. Drug development itself is a risky 
process as only 30% of launched products achieve enough profits so as to pay back the 
development investment. In addition to this, the authorities determine whether a pro-
ject can continue or not. That is why risk analysis is very significant and should be tak-
en into account by the project managers of the company. 
8.1 Risk factors 
The risks that exist in the pharmaceutical industry, because of the complexity that 
characterizes it, can be listed in the following categories. 
8.1.1 Technical risks 
The technical part of the product development process is very complex as it is consist-
ed of many procedures. The formulation of a product and the analysis that should be 
done beforehand are very crucial and determinant for the success of the product. Any 
mistake that can be done in this part automatically destroys the project. In addition to 
this, the clinical trials, the production and all the process development are affected by 
any obstacles that can appear and delay or cancel the project. Furthermore, it is possi-
ble that some clinical and toxicological studies may have undesired outcome and this is 
another factor that can stop the whole process. 
8.1.2 Partnership 
Panakia is an analytic, contract company which offers as well consultancy and business 
intelligence services. This means that part of its function is based on the cooperation 
with other companies which will require Panakia’s services. The credibility of such 
companies and a non-satisfactory cooperation are some other risks that exist in the 
working environment of a company like Panakia. 
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8.1.3 Resource availability 
For the function of a pharmaceutical company the resources that are needed have to 
do both with raw materials and with people as well. To start with, raw materials are 
very expensive and sometimes difficult to find because of the fact that Greece imports 
a significant quantity of the substances that are required for the formulation of the 
medicine. The capital control that has been imposed to Greece makes the situation 
more difficult as all the imports have been affected. In addition to this, the personnel is 
an important factor that determines the success of a project and of a company in gen-
eral. That is why when the required knowledge does not exist and the personnel is 
characterized by insufficient scientific experience, a project can be led to failure, thing 
very costly for the company. Panakia Pharma will continuously train fresh graduate to 
prepare them for the Greek market and to prepare a pool of talent to support the 
company continuous growth. 
8.1.4 Regulation 
A very close monitoring of the regulation that exists not only in Greece but worldwide 
is needed. Failure of compliance of the products with the regulatory system means au-
tomatically that the authorities ban the launching of the product. Also the process of 
the development of the products is highly regulated and these regulations may change 
from time to time. For that reason all pharmaceutical companies should closely moni-
tor these changes and adapt them. 
8.1.5 Project management/ Strategy 
The completion of the project itself may be risky if it is not organized carefully be ex-
perts who take into account all the factors that determine its success. The scope of the 
project should be clear from the beginning and the cost should be carefully estimated. 
The schedule is as well very important as companies like Panakia have the pressure of 
time because specific products and services should be completed within specific peri-
ods of time. If the project is not completed within the limits that are set beforehand, 
this may cost a lot of money to the company and have a negative impact on its reputa-
tion. The strategy that a company follows is determinant for its function and the out-
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comes so biased and inefficient strategies risk the future of the company. In addition 
to this, a close research is needed for the company’s partners so as to ensure that 
problems with the credibility and the cooperation with other companies will not ap-
pear.  
8.1.6 Launching of products 
Another risk is hiding at the launching phase of a product. Commercialization is very 
crucial for the future sales of a pharmaceutical product and some surveys show that 
two-thirds of products fail to meet prelaunch consensus sales expectations for the first 
year in the market. This has cost a lot of money to some pharma companies who failed 
to launch correctly and efficiently their products in the market. 
8.1.7 High R&D costs/ Costly methods of drug development 
Drug development is a costly procedure and it requires a lot of time to be completed. 
Also, the R&D costs are extremely high but it is a very important part of the company 
which cannot be extracted. Thus, the company needs a big capital in order to afford all 
this and when these procedures end with no satisfactory results, this costs a lot of 
money to the company. 
8.1.8 External factors 
We should not forget that a lot of factors which have to do with the environment of 
the company may create important risks that the company should confront with. The 
scientific advances of the competitors threat Panakia and this is due to the fact that 
because of the speed of technological changes new methods and molecules are being 
introduced within a short period of time, which means that new competitive products 
are being developed. In addition to this, scientific recommendations play a significant 
role to the sales of a product and any negative comments jeopardize the future of the 
medicine. Furthermore, the market itself is a risky factor that the company should take 
into account because of the fact that the worldwide financial crisis has affected all the 
sectors, including the pharmaceutical market. The respiratory market is very crowded 
and this creates another risk that the company needs to deal with. In addition to this, 
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the governmental policy which is followed in Greece affects negatively the prices of all 
medicine; unexpected changes in inflation rate may as well have a negative impact on 
the finance of the company. Lastly, the reluctance of the patients and potential cus-
tomers towards Panakia because it is a start-up company, should be taken into ac-
count. 
8.2 Risk management 
In a so complex area as the pharmaceutical sector, risk management is the most im-
portant project that is responsible for the success or failure of a company. Because of 
the fact that a lot of factors, which were analyzed before, are a continuous threat for 
the proper function of a pharmaceutical company, a specific methodology should be 
used in every case. Also, there should be a clear clarification of the roles and responsi-
bilities that each person should have in the risk management project and a calculation 
of the budget that is needed to deal with all these risks should take place. Additionally, 
the time frame of the project should be determined and a scoring system should pro-
vide information about the importance of the various risks. After this, the manage-
ment should continue with the reporting of formats and the tracking of the risks. We 
should not forget that the most crucial and important steps are the identification and 
analysis of the existing risks. 
8.2.1. Risk management of potential threats 
As far as it concerns the technical part, there should be an early detection of any pos-
sible malfunction that may occur. That is why a program leader should be set in order 
to be able to confront all this. Because of the fact that in the drug development pro-
cess the results are not always the expected ones and some projects may end up in a 
complete failure, the company should always develop back up strategies and should 
perform parallel research for different indications of the particular product. In addition 
to this, undesired outcome can be dealt with the elimination of all the poor prospects 
in an early stage. Furthermore, regulatory threats can be omitted with the creation of 
a specific plan in which regulatory and manufacturing standards will be consistently 
applied. Also, an inspection program should be operated in a coordinated and syner-
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gistic manner. The amount of resources needed should be calculated in detail and an 
easier access to markets should be found in order for the company not to face any 
problems with the raw material supply. As far as it concerns the personnel, experi-
enced specialists and visionary people should be selected to staff the company be-
cause the proper function of the company is required and only specialists can put 
through so difficult tasks. Furthermore, the risk of failed development projects must be 
covered by very successful products and this means that the company should have a 
wide portfolio of products which it can use in such cases. Complacency is not some-
thing that should characterize companies that operate in the pharmaceutical market. 
The high cost of R&D and drug development is very crucial for the future of the com-
pany as big investments are needed to cover these expenses. A solution to this is to 
have enough products in the pipeline of the company so as to recover the R&D costs.  
Additionally, long and expensive clinical trials should be avoided because Panakia has a 
specific timeline within which it should bring the expected profits. Panakia must estab-
lish unmet needs in the disease area, in order to succeed in giving the correct boost to 
its products. Investing in marketing is the essential solution in order to have the best 
results with the launching of a product. In this way customers are convinced about the 
effectiveness of our products, thing that helps with their promotion. For that reason, 
experienced project leaders should be responsible for each project. The creation of a 
planning horizon is significant and all the procedures that will be followed should be 
defined in advance. The proper management of the work plan and the monitoring of 
the budget should be a priority of the project leader. All issues should be resolved as 
quickly as possible so as to have the expected outcome. The external risks that may 
threat a company like Panakia, as it was described before, are mainly the competitors 
in the pharmaceutical respiratory area and the market itself. That is why the company 
should invest in innovation as well, by using innovative methods of drug formulation 
and development processes in general. It is of high importance the close monitoring of 
the respiratory market, especially nowadays that significant changes are occurring eve-
ryday with companies both entering and leaving the Greek market. In addition to this, 
through intensive research the company can decide on the products that it should 
launch based on the customers’ needs and preferences. The company should update 
its data continuously, as it gives critical feedback for the progress of the drug devel-
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opment and for the future of the company. As Reynolds (1998) recommended, vari-
ances should be raised from any level of the project team and a risk register should be 
used to estimate future costs, variances and actions. Risk mitigation and project en-
hancement should be controlled by special teams. Also, risk management should be a 
topic in the team’s weekly meetings. (Reynolds 1998: 93, 96-98) 
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Conclusions 
The main challenge that the Greek pharmaceutical market is facing is the instability in 
the pricing of the medicine and the unpredicted government policies that are followed. 
The respiratory area is an area which offers a great deal of potential to companies 
which are focusing on the production of respiratory products, as the number of the 
patients who suffer from pulmonary diseases is increasing every day. Another area 
which is becoming very attractive nowadays in Greece is the area of generics. The gov-
ernment with new laws obliges the doctors to prescribe generics in a percentage of 
almost 60% of the total amount of medicine that they prescribe monthly to their pa-
tients. This means that new opportunities are offered for the creation of Greek phar-
maceutical companies which produce generics. 
Panakia is a company that will focus on the development of cost effective respiratory 
generic therapies especially in a period that big companies are experiencing several 
patent expires. Therefore, Panakia will enter the pharmaceutical market by firstly de-
veloping innovative molecules and assisting big pharmaceutical companies with its 
consulting and analytical methods. Furthermore, it will develop cost effective generic 
drugs so as to fulfill the needs of the Greek market and manage to get an important 
market share in the respiratory area. That is why it will develop its business plan in the 
following three phases: 
1. Phase 1: In this phase Panakia will create a Contract Research Organization with fo-
cus on respiratory diseases. It will offer consultancy and operational services to other 
pharmaceutical companies which want to develop medicine to treat pulmonary dis-
eases. 
2. Phase 2: In the second phase Panakia will create manufacturing facilities to support 
the development of inhalation products. Also facilities will be created for the perfor-
mance of clinical trials and for the analytical services that the company will offer .This 
phase is the most demanding phase that is why the capital that is needed for its func-
tion is much bigger that in the other two phases. 
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3. Phase 3: In the last phase, Panakia will develop new forms of therapies for the 
treatment of pulmonary diseases. It will also market product lines across global mar-
kets and continue to expand through internal innovation and through the acquisition 
of products and technologies that support all the previous. The creation of informa-
tional programs both for patients and for doctors are within the company’s priorities. 
Through this, the launching of new products can be significantly helped and its prod-
ucts will become more attractive to the patients. 
So, even though the Greek market is regarded by many as a high-risk market, there is 
still enough room for innovation and for development from which the country itself 
can benefit. 
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Appendix 
A. The questionnaire of the interviewers 
1. How do you see the current pharmaceutical market in Greece? 
2. Where do you see the main focus of the respiratory market today? 
3. Is the market growing volumewise and saleswise? 
4. Where do you see the current risk of instability of the Greek market? 
5. Do you see any companiescoming in or abandoning the Greek market? 
6 . Do you see any opportunities for the Greek companies to take over the market? 
7. Can Innovation drive growth in the Greek market? 
8. Which are the absolut critical success factors that a company needs to have in order to be 
able to operate in Greece? 
9. Which differences exist between the Greek and the European pharmaceutical market? 
10. Why (if not) you have decided not to operate in Greece? 
B. Individual answers 
1. Avgui Charalambous Ph.D , Head of Business Development at ELPEN Pharma, 
Greece 
Dr. Charalambous emphasized that the current pharmaceutical market in Greece is 
characterized by a lot of changes which have to do mainly with the reduction of the 
price of the medicine. The pharmaceutical companies have lost 15% from their reve-
nues due to the claw backs and rebate that have been enforced to them. As a result 
this creates a negative atmosphere for many multinational companies in the Greek 
market but at the same time it offers opportunities for the development of new 
Greek companies. COPD and Asthma are the main diseases on which respiratory 
market focuses and she explains that the current instability in the Greek market is 
due to the unpredictable policy that the government follows with price reduction 
and import of medicine from countries with lower prices like India. ELPEN itself with 
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the development of generic products has not experienced any loses in their market 
share; instead there is a steady increase in their volumes and sales in the market, 
covering the 23% of the whole market. As far as it concerns the critical success fac-
tors, Mrs. Charalampous says that it is important for a company to recognize the op-
portunities, invest on innovative products and R&D, have dedicated employees and 
reasonable prices. Also, there needs to be a stable environment for the companies to 
develop and the support of the government through the policy that it follows, is as 
important as all the other factors. 
2. Dimitris Alexandropoulos, National Sales Manager COPD, Novartis Pharma Hel-
las, Greece 
Mr. Alexandropoulos explained that nowadays the respiratory market is focused on 
the chronic obstructive pulmonary disease as well as asthma. The number of pa-
tients that suffer from these two particular diseases are increasing daily and this is 
the reason why the companies invest on respiratory medicine. Also sales-wise, he 
commented that the market is growing because of the development of new products 
and that Novartis itself is not willing to abandon the Greek market despite the nega-
tive climate that exists, instead they withdraw old products which do not offer a lot 
of profit and they present new products to the market. He emphasized the im-
portance of the patient access and that innovation is the key for the survival of the 
companies in Greece. As far as it concerns the critical success factors for continuing 
operating in Greece, Mr. Alexandropoulos mentioned that companies should be in-
novative and should have a wide portfolio of products so as to diversify the risk of 
instability that exists nowadays. In addition to this, the government is the most im-
portant factor that controls the Greek market and the prices of the medicine and 
new laws and boundaries should be set so as not to affect negative the stability of 
the market. The risk of instability is high because of the governmental strategy for 
the reduction of the prices in order to decrease the public spending on pharmaceuti-
cals. The profitability of Novartis itself was affected dramatically as it was decreased 
by 50% thing that was balanced with the introduction of new respiratory products. 
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3. Fadi Eskandar, Senior Manager of Respiratory portfolio, Skyepharma AG, Swit-
zerland 
Dr. Fadi Eskandar described the current pharmaceutical market as a market which 
faces major challenges following the worldwide policy of health care cost reduction. 
Volume-wise, the market is growing because of the fact that the number of patients 
who live longer under chronic diseases, is increasing. Sales-wise, there is a mixed 
view, as we meet a growing market in the Asia-Pacific, middle East and USA but in 
Europe the situation differs because of the financial crisis. He underlined that the 
focus in the respiratory market will be on branded generic area, developing new in-
halers with lower cost. As Skyepharma has not entered into the Greek market, Mr. 
Eskandar explained that this occurred due to the fact that the Greek market is a low 
cost market in comparison to other European countries where prices and profits are 
higher. In addition to this, the Greek pharmaceutical market depends on a govern-
mental health insurance system and the government follows a cost reduction policy. 
Also, the Greek market is becoming more prices sensitive to enter into it. Many 
companies are concerned that a low market access price in Greece may lead to a re-
duction in the medicine price in other EU countries mainly due to the reference list-
ing across EU countries. This leads to a delay in market entry in Greece in many cases 
but even terminating planned launches of new products in Greece. More connectivi-
ty between patients and physicians is needed to ensure that patients are well con-
trolled under therapy and to reduce hospitalization, which alternatively will led to a 
better quality of life. As far as it concerns the critical success factors that a company 
needs to enter the Greek market he focused on the fulfilling of the customer needs 
and on the efficient operation of companies with quick product development and 
low cost of operation. 
4. Mr. Joseph Fam, Project Manager of the Golf countries in Sanofi Aventis, UAE. 
Mr. Fam explained that the pharmaceutical market is growing with a slow speed be-
cause of the fact that a lot of shifts of population take place and there are a lot of 
expatriates. This means that consumption of products decreases locally and growth 
results only from new patients. He emphasizes the fact that a lot of companies now-
adays decide to leave markets that are considered to be high risk markets like 
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Greece, and then they turn to local distributors or they leave sales representatives so 
as to promote their products. In addition to this, he believes that the critical success 
factors in order for a company to operate in Greece are the correct pricing, the good 
and detailed analysis of the market’s needs and the understanding of the local cul-
ture. Also, the market access is extremely important and the government’s policy 
plays a significant role to the development of a company. The regulation of the pric-
ing of the products is very crucial as frequent changes jeopardy the stability of the 
market. Furthermore, bureaucracy is an obstacle in many countries including Greece 
and to his opinion a company needs to be able to develop interaction with the gov-
ernment. Mr Fam explained the reasons why the Greek market is considered to be 
an unattractive market for foreign investors. He referred to the financial crisis and 
the political instability that has created a prejudice about the Greek market. Also, he 
notices that most of the multinational companies select other markets rather than 
Greece because they can sell their products in higher prices abroad so they make 
bigger profits. Furthermore, he referred to the creation of generics which have be-
come a significant part of the pharmaceutical companies. The number of molecules 
which can be manufactured is less than before and many products have gone out of 
patent. This creates a lot of opportunities for companies to start developing generics 
and through this to take over important market shares. Lastly, he emphasized the 
new trend that exists in the pharmaceutical market which is the cooperation of big 
companies with small contract companies for the development of new molecules 
and generic products. He mentioned as examples Pfizer and Sanofi that both created 
such cooperation as they want to spend less on R&D and save as well time and ef-
fort.  
5. Panos Spyrou, Business Unit Director of AstraZeneca, Greece 
Mr. Spyrou described the Greek market as a market which constantly shrinks be-
cause of the pressure that is imposed on it due to the reduction in the pharmaceuti-
cal expenditure that the company wants to accomplish. He predicted that in the next 
3-5 years the Greek market is not going to be an attractive market for new products 
as generics will be the target of the government in order to have medicine with low-
er prices. The respiratory market focuses on COPD and Asthma and lately on IPF and 
the development of monoclinic antibodies is the new technology that many pharma-
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ceutical companies are adapting for the creation of innovative products. In addition 
to this, new molecules are being introduced constantly, thing that gives a boost to 
the market. He argues that scientific research is not supported in Greece and the 
market has lost its attractiveness because of the constant reduction of the prices. 
AstraZeneca itself has lost some market share of the respiratory market because of 
the change in the prices and the creation of cheaper products. The increase of the 
rebates and claw backs has decreased the profit of the company.  Some multination-
al companies, like Teva, have starting abandoning the Greek market by giving the 
management of their products in Greece to their representatives so as not to have a 
base in Greece and to avoid operating expenses. Mr. Spyrou believes that in order 
for a company to continue operating in Greece, it needs to have an adequate portfo-
lio of products with no exaggerations, efficient ways to promote its products with 
low cost, detailed segmentation of the market and offer high quality products with 
high therapeutic value to the patients. 
C. Share of generics in the total pharmaceutical market, 2013 (or nearest year) 
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D. Causes of deaths in Greece 
 
E. Health expenditure as a percentage of GDP (OECD countries) 
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F. Segmentation of the Greek pharmaceutical market 
 
